Anzeige
Meldung des Tages: KI für Verteidigung! Der Countdown zu einer der heißesten AI-Hightech-Stories 2026 beginnt jetzt

BioMarin Pharmaceutical Aktie News

Aktie
WKN:  924801 ISIN:  US09061G1013 US-Symbol:  BMRN Branche:  Biotechnologie Land:  USA
56,65 $
-0,13 $
-0,23%
47,294 € 17:47:23 Uhr
Depot/Watchlist
Marktkapitalisierung *
9,78 Mrd. €
Streubesitz
1,13%
KGV
16,80
Index-Zuordnung
Nasdaq Composite Index

BioMarin Pharmaceutical News

16.05.25 - PR Newswire
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma PR Newswire
12.05.25 - PR Newswire
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings PR Newswire
01.05.25 - PR Newswire
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance PR Newswire
17.04.25 - PR Newswire
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET PR Newswire
02.04.25 - PR Newswire
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-​pqpz) in Adolescents with Phenylketonuria PR Newswire
20.03.25 - PR Newswire
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-​World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with ...
25.02.25 - PR Newswire
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA PR Newswire
24.02.25 - PR Newswire
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors PR Newswire
19.02.25 - PR Newswire
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance PR Newswire
05.02.25 - PR Newswire
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET PR Newswire

Newssuche

Videos

newspaper
13:00 Uhr -6,03%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »